AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23823584 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrients with sugar
Number of subjects: 414
Study 23823584 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrients with non-nutritive sweetener
Number of subjects: 414
Study 23823584 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar with micronutrients
Number of subjects: 414
Study 23823584 — intervention group
Group type: COMPARATOR
Intervention: Micronutrients alone
Number of subjects: 414
Study 23823584 — intervention group
Group type: COMPARATOR
Intervention: Sugar alone
Number of subjects: 414
Study 21130446 — intervention group
Group type: EXPERIMENTAL
Intervention: 400‐μg sublingual misoprostol plus routine uterotonics
Number of subjects: 1345
Study 21130446 — intervention group
Group type: COMPARATOR
Intervention: Routine uterotonics
Number of subjects: 1345
Study 21130446 — intervention group
Group type: EXPERIMENTAL
Intervention: 400‐μg sublingual misoprostol
Number of subjects: 1345
Study 21130446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1345
Study 19897985 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade intramedullary nail
Number of subjects: 70
Study 19897985 — intervention group
Group type: COMPARATOR
Intervention: Retrograde intramedullary nail
Number of subjects: 70
Study 19897985 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic evaluation
Number of subjects: 70
Study 17522509 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB)
Number of subjects: 315
Study 15241630 — intervention group
Group type: EXPERIMENTAL
Intervention: ECD registration with count difference (CD)
Number of subjects: 25
Study 15241630 — intervention group
Group type: EXPERIMENTAL
Intervention: ECD registration with normalized mutual information (NMI)
Number of subjects: 25
Study 15241630 — intervention group
Group type: EXPERIMENTAL
Intervention: TCT registration with count difference (CD)
Number of subjects: 25
Study 15241630 — intervention group
Group type: EXPERIMENTAL
Intervention: TCT registration with normalized mutual information (NMI)
Number of subjects: 25
Study 15241630 — intervention group
Group type: EXPERIMENTAL
Intervention: TCT registration with NMI
Number of subjects: 25
Study 11589872 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted in situ keratomileusis (LASIK)
Number of subjects: 20
Study 9834799 — intervention group
Group type: EXPERIMENTAL
Intervention: DBS (double burst stimulation)
Number of subjects: 60
Study 9834799 — intervention group
Group type: COMPARATOR
Intervention: CC (clinical criteria)
Number of subjects: 60
Study 7857516 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 300 mg hypericum extract
Number of subjects: 105
Study 7857516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 799996 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol tartrate (1, 2, and 4 mg)
Number of subjects: 124
Study 799996 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine lactate (30 and 60 mg)
Number of subjects: 124
Study 31644514 — intervention group
Group type: EXPERIMENTAL
Intervention: Tritube with flow-controlled ventilation (FCV)
Number of subjects: 40
Study 31644514 — intervention group
Group type: COMPARATOR
Intervention: Microlaryngeal tube (MLT) with volume-controlled ventilation (VCV)
Number of subjects: 40
Study 28704733 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent theta-burst stimulation (potentiation protocol)
Number of subjects: 15
Study 28704733 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent theta-burst stimulation combined with a depotentiation protocol (short continuous theta-burst stimulation)
Number of subjects: 15
Study 28704733 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 15
Study 25964369 — intervention group
Group type: EXPERIMENTAL
Intervention: Curriculum
Number of subjects: 5440
Study 25964369 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory daily hand washing before lunch
Number of subjects: 5440
Study 25964369 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra cleaning of school toilets
Number of subjects: 5440
Study 25964369 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 5440
Study 23529779 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic thyroidectomy
Number of subjects: 90
Study 23529779 — intervention group
Group type: COMPARATOR
Intervention: Conventional open thyroidectomy
Number of subjects: 90
Study 22282730 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implant placement (54 patients)
Number of subjects: 106
Study 22282730 — intervention group
Group type: COMPARATOR
Intervention: Delayed placement (52 patients)
Number of subjects: 106
Study 22282730 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 106
Study 18668226 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam 0.5 mg
Number of subjects: 41
Study 18668226 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam 1.0 mg
Number of subjects: 41
Study 18668226 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 41
Study 17042845 — intervention group
Group type: EXPERIMENTAL
Intervention: Study lecture with images of a train set delivering rocks (analogy to oxygen delivery)
Number of subjects: 0
Study 17042845 — intervention group
Group type: COMPARATOR
Intervention: Control lecture (oxygen delivery and hypoxaemia)
Number of subjects: 0
Study 14581110 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion for 90 minutes
Number of subjects: 0
Study 14581110 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of S-ketamine
Number of subjects: 0
Study 14581110 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 10969200 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance measures computed from PCA of EMG waveforms during trunk movements
Number of subjects: 33
Study 10969200 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliability analysis of distance measures
Number of subjects: 33
Study 9102590 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin sodium, 2500 IU
Number of subjects: 30
Study 9102590 — intervention group
Group type: COMPARATOR
Intervention: Nadroparin calcium, 3075 IU
Number of subjects: 30
Study 1615227 — intervention group
Group type: EXPERIMENTAL
Intervention: End-tidal PO2 at 45 Torr
Number of subjects: 6
Study 1615227 — intervention group
Group type: EXPERIMENTAL
Intervention: End-tidal PO2 at 50 Torr
Number of subjects: 6
Study 1615227 — intervention group
Group type: EXPERIMENTAL
Intervention: End-tidal PO2 at 55 Torr
Number of subjects: 6
Study 1615227 — intervention group
Group type: EXPERIMENTAL
Intervention: End-tidal PO2 at 65 Torr
Number of subjects: 6
Study 1615227 — intervention group
Group type: EXPERIMENTAL
Intervention: End-tidal PO2 at 75 Torr
Number of subjects: 6
Study 1615227 — intervention group
Group type: EXPERIMENTAL
Intervention: Relief of hypoxia
Number of subjects: 6
Study 6486249 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling plus cognitive‐behavioral psychotherapy
Number of subjects: 110
Study 6486249 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling plus supportive‐expressive psychotherapy
Number of subjects: 110
Study 6486249 — intervention group
Group type: COMPARATOR
Intervention: Paraprofessional drug counseling alone
Number of subjects: 110
Study 6486249 — intervention group
Group type: COMPARATOR
Intervention: Counseling alone
Number of subjects: 110
Study 31328399 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconditional monetary incentive (£5 gift voucher with questionnaires)
Number of subjects: 1079
Study 31328399 — intervention group
Group type: COMPARATOR
Intervention: Conditional monetary incentive (£5 gift voucher promised after returning questionnaires)
Number of subjects: 1079
Study 31328399 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconditional monetary incentive
Number of subjects: 1079
Study 31328399 — intervention group
Group type: COMPARATOR
Intervention: Conditional monetary incentive
Number of subjects: 1079
Study 31030876 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased avoidance behavior and unhelpful gastrointestinal (GI) cognitions
Number of subjects: 557
Study 31030876 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased control behaviors
Number of subjects: 557
Study 31030876 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive and behavioral differences across Rome III classified IBS subtypes
Number of subjects: 557
Study 31030876 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological factors
Number of subjects: 557
Study 31030876 — intervention group
Group type: COMPARATOR
Intervention: No differences in anxiety, depression, overall symptom severity, or work and social adjustment
Number of subjects: 557
Study 27981431 — intervention group
Group type: EXPERIMENTAL
Intervention: enzalutamide 160 mg/day
Number of subjects: 1717
Study 27981431 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1717
Study 25720808 — intervention group
Group type: EXPERIMENTAL
Intervention: Marbofloxacin (2 mg/kg, IV, once; MRFX group)
Number of subjects: 48
Study 25720808 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrofloxacin (5 mg/kg, IV, once; ERFX group)
Number of subjects: 48
Study 25720808 — intervention group
Group type: COMPARATOR
Intervention: Control (saline solution 0.9% NaCl, 10 ml, IV, once)
Number of subjects: 48
Study 25720808 — intervention group
Group type: EXPERIMENTAL
Intervention: Marbofloxacin (2 mg/kg, IV, once; MRFX group) and Enrofloxacin (5 mg/kg, IV, once; ERFX group)
Number of subjects: 48
Study 24381153 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 180
Study 24381153 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOAC)
Number of subjects: 180
Study 24381153 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 180
Study 24381153 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 180
Study 24381153 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 180
Study 24381153 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall anticoagulation preference tool
Number of subjects: 180
Study 22459559 — intervention group
Group type: EXPERIMENTAL
Intervention: Enactment condition
Number of subjects: 0
Study 22459559 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory condition
Number of subjects: 0
Study 22459559 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual condition
Number of subjects: 0
Study 19873912 — intervention group
Group type: EXPERIMENTAL
Intervention: Linggui Bafa acupuncture treatment
Number of subjects: 120
Study 19873912 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 120
Study 19873912 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acupuncture or oral medication)
Number of subjects: 120
Study 17398061 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.5 microg/kg)
Number of subjects: 40
Study 17398061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15304576 — intervention group
Group type: EXPERIMENTAL
Intervention: Body temperature >37.5 degrees C
Number of subjects: 266
Study 15304576 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil count (by 1,000-unit increase)
Number of subjects: 266
Study 15304576 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum fibrinogen levels >523 mg/dL
Number of subjects: 266
Study 15304576 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ICH growth
Number of subjects: 266
Study 15304576 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular bleeding
Number of subjects: 266
Study 15304576 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest systolic blood pressure (by 10-unit increase)
Number of subjects: 266
Study 11210398 — intervention group
Group type: COMPARATOR
Intervention: Fasting state (no food)
Number of subjects: 15
Study 11210398 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 15
Study 11210398 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat meal
Number of subjects: 15
Study 9762782 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 72 microg (4+4+4 doses)
Number of subjects: 27
Study 9762782 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline 6 mg (4+4+4 doses)
Number of subjects: 27
Study 9762782 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 120 microg (8+6+6 doses)
Number of subjects: 27
Study 9762782 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline 10 mg (8+6+6 doses)
Number of subjects: 27
Study 7531054 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (QOL) instruments analysis
Number of subjects: 0
Study 7531054 — intervention group
Group type: EXPERIMENTAL
Intervention: Three possible approaches to the analysis of QOL data
Number of subjects: 0
Study 2894490 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous APSAC (30 unit dose)
Number of subjects: 1004
Study 2894490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1004
Study 30068306 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin-collagen sponge with systemic antibiotic therapy
Number of subjects: 88
Study 30068306 — intervention group
Group type: COMPARATOR
Intervention: Systemic antibiotics alone (Control)
Number of subjects: 88
Study 26825817 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fluids (IVF)
Number of subjects: 570
Study 26825817 — intervention group
Group type: COMPARATOR
Intervention: No intravenous fluids (IVF)
Number of subjects: 570
Study 25298250 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency surgery
Number of subjects: 58
Study 25298250 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 58
Study 25298250 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting with perforation
Number of subjects: 58
Study 25298250 — intervention group
Group type: COMPARATOR
Intervention: Unperforated stenting
Number of subjects: 58
Study 23711810 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided DES implantation
Number of subjects: 1574
Study 23711810 — intervention group
Group type: COMPARATOR
Intervention: Angiographically guided DES implantation
Number of subjects: 1574
Study 23711810 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided DES implantation in patients with diabetes mellitus
Number of subjects: 1574
Study 23711810 — intervention group
Group type: COMPARATOR
Intervention: Angiographically guided DES implantation in patients with diabetes mellitus
Number of subjects: 1574
Study 23711810 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided DES implantation in patients with acute coronary syndrome
Number of subjects: 1574
Study 23711810 — intervention group
Group type: COMPARATOR
Intervention: Angiographically guided DES implantation in patients with acute coronary syndrome
Number of subjects: 1574
Study 19925497 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release omeprazole 40 mg suspension o.m. for 7 days
Number of subjects: 12
Study 19925497 — intervention group
Group type: COMPARATOR
Intervention: Delayed-release omeprazole 40 mg capsule o.m. for 7 days
Number of subjects: 12
Study 17917501 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg plus amlodipine 5 mg
Number of subjects: 545
Study 17917501 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 545
Study 17917501 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 545
Study 15476129 — intervention group
Group type: EXPERIMENTAL
Intervention: Positioning (four different positions)
Number of subjects: 8
Study 15476129 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's milk or preterm formula (prior to positioning)
Number of subjects: 8
Study 11308066 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatologist visit in the last 12 months
Number of subjects: 2533
Study 11308066 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioner visit in the last 12 months
Number of subjects: 2533
Study 11308066 — intervention group
Group type: EXPERIMENTAL
Intervention: Low involvement score
Number of subjects: 2533
Study 11308066 — intervention group
Group type: EXPERIMENTAL
Intervention: High education level and health service provided by rheumatologists
Number of subjects: 2533
Study 11308066 — intervention group
Group type: EXPERIMENTAL
Intervention: Good mental health and high involvement
Number of subjects: 2533
Study 11308066 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pain level and good mental health
Number of subjects: 2533
Study 11308066 — intervention group
Group type: EXPERIMENTAL
Intervention: Low score on involvement
Number of subjects: 2533
Study 9602577 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 150 micrograms kg-1
Number of subjects: 216
Study 9602577 — intervention group
Group type: COMPARATOR
Intervention: Perphenazine 70 micrograms kg-1
Number of subjects: 216
Study 8290195 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin (3 g every 6 hours) and Tazobactam (375 mg every 6 hours)
Number of subjects: 299
Study 8290195 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin (900 mg every 8 hours) and Gentamicin (2.5-5.0 mg/kg/day in three divided doses)
Number of subjects: 299
Study 8290195 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam
Number of subjects: 299
Study 8290195 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin-gentamicin
Number of subjects: 299
Study 3187936 — intervention group
Group type: EXPERIMENTAL
Intervention: 135 g of canned mackerel paste (experimental group)
Number of subjects: 82
Study 3187936 — intervention group
Group type: COMPARATOR
Intervention: Meat paste (control group)
Number of subjects: 82
Study 5763957 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of phenylpropanolamine taken orally
Number of subjects: 3
Study 5763957 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of phenylpropanolamine taken orally
Number of subjects: 3
Study 5763957 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of phenylpropanolamine taken orally (in a subject taking tranylcypromine)
Number of subjects: 3
Study 5763957 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprietary cough linctus containing 50 mg of phenylpropanolamine (in a subject taking tranylcypromine)
Number of subjects: 3
Study 5763957 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine in free form
Number of subjects: 3
Study 5763957 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of phentolamine
Number of subjects: 3
Study 5763957 — intervention group
Group type: COMPARATOR
Intervention: Slow-release form of phenylpropanolamine
Number of subjects: 3
Study 30107789 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion Simulation (MSim)
Number of subjects: 0
Study 30107789 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV)
Number of subjects: 0
Study 30107789 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Motion Simulation and Whole Body Vibration (MSim + WBV)
Number of subjects: 0
Study 30107789 — intervention group
Group type: COMPARATOR
Intervention: Regular care (Control)
Number of subjects: 0
Study 30107789 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive exercise (all forms)
Number of subjects: 0
Study 26867199 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten intake (5.6 g/day) for 7 days after a 3-week gluten-free diet (GFD)
Number of subjects: 140
Study 26867199 — intervention group
Group type: COMPARATOR
Intervention: Placebo ingestion
Number of subjects: 140
Study 26867199 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD)
Number of subjects: 140
Study 25711318 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment at a CD4 cell count of 500 cells/μL or higher
Number of subjects: 0
Study 25711318 — intervention group
Group type: COMPARATOR
Intervention: Deferring treatment until the CD4 cell count decreases to 350 cells/μL or until AIDS develops
Number of subjects: 0
Study 23809257 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid model of combined modified constraint induced movement therapy (mCIMT) followed by intensive bimanual training (COMBiT)
Number of subjects: 50
Study 23809257 — intervention group
Group type: COMPARATOR
Intervention: Distributed model of standard occupational therapy and physiotherapy care (SC)
Number of subjects: 50
Study 21079425 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT)
Number of subjects: 24221
Study 18449029 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolones (ciprofloxacin, ofloxacin, pefloxacin)
Number of subjects: 194
Study 18449029 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolones
Number of subjects: 194
Study 18449029 — intervention group
Group type: COMPARATOR
Intervention: β-lactams
Number of subjects: 194
Study 17079587 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy (3 one-on-one sessions per week for 8 weeks, followed by a home program for another 6 weeks)
Number of subjects: 81
Study 17079587 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 81
Study 17079587 — intervention group
Group type: COMPARATOR
Intervention: Equal-contact exercise placebo intervention
Number of subjects: 81
Study 17079587 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 81
Study 15514272 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/d iron supplementation for 12 months
Number of subjects: 614
Study 15514272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 614
Study 11167929 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric diet with 2% carbohydrates
Number of subjects: 6
Study 11167929 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric diet with 44% carbohydrates
Number of subjects: 6
Study 11167929 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric diet with 85% carbohydrates
Number of subjects: 6
Study 9919895 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg daily for 2 weeks
Number of subjects: 114
Study 9919895 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole 200 mg daily for 1 week
Number of subjects: 114
Study 7850232 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescent method using fluorophore K-35 for measuring total albumin concentration in human blood serum
Number of subjects: 0
Study 7850232 — intervention group
Group type: COMPARATOR
Intervention: Bromocresol purple method
Number of subjects: 0